特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
916573

ブラジルのヒトインスリン製剤市場:2019年~2023年

Human Insulin Drugs Market in Brazil by Distribution Channel, Product, and Application - Forecast and Analysis 2019-2023

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 135 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
ブラジルのヒトインスリン製剤市場:2019年~2023年
出版日: 2019年10月16日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 135 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ブラジルのヒトインスリン製剤市場は、ブラジルでの糖尿病の有病率の上昇、人口転換、戦略的提携などが成長促進要因となり、予測期間中に5%以上のCAGRで拡大する見込みです。しかし、高額なヒトインスリン製剤、病因不明なI型糖尿病、および入手困難な特定のバイオマーカーなどの要因が、予測期間にわたってブラジルのヒトインスリン製剤市場の成長を妨げる可能性があります。

当レポートでは、ブラジルのヒトインスリン製剤市場について調査分析し、市場規模および成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 インスリン:概要

第7章 市場セグメンテーション化:流通チャネル別

  • 市場セグメンテーション:流通チャネル別
  • 流通チャネル別比較:市場規模および予測(2018年~2023年)
  • 小売
  • 病院
  • 市場機会:流通チャネル別

第8章 市場セグメンテーション化:製品別

  • 市場セグメンテーション:製品別
  • 製品別比較:市場規模および予測(2018年~2023年)
  • 基礎インスリンアナログ製剤
  • NPH
  • 市場機会:製品別

第9章 顧客情勢

第10章 市場セグメンテーション:アプリケーション別

  • 市場セグメンテーション:アプリケーション別
  • アプリケーション別比較:市場規模および予測(2018年~2023年)
  • I型糖尿病
  • II型糖尿病
  • 市場機会:アプリケーション別

第11章 意思決定の枠組み

第12章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第13章 市場動向

  • バイオシミラーの出現
  • ベンダーによる取り組みの増加
  • 技術の進歩

第14章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競争シナリオ

第15章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Biocon Ltd.
  • Eli Lilly and Co.
  • Novo Nordisk AS
  • Sanofi
  • Wockhardt Ltd.

第16章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第17章 TECHNAVIOについて

図表

LIST OF EXHIBITS:

  • Exhibit 01: Vendors: Key offerings
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Country market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Health finance indicator in Brazil (1995-2011)
  • Exhibit 10: Timeline of Brazil's unified health system
  • Exhibit 11: Country market: Year-over-year growth 2019-2023 (%)
  • Exhibit 12: Five forces analysis 2018
  • Exhibit 13: Five forces analysis 2023
  • Exhibit 14: Bargaining power of buyers
  • Exhibit 15: Bargaining power of suppliers
  • Exhibit 16: Threat of new entrants
  • Exhibit 17: Threat of substitutes
  • Exhibit 18: Threat of rivalry
  • Exhibit 19: Market condition - Five forces 2018
  • Exhibit 20: Blood glucose control
  • Exhibit 21: Types of human insulin analog
  • Exhibit 22: Distribution channel - Market share 2018-2023 (%)
  • Exhibit 23: Comparison by distribution channel
  • Exhibit 24: Retail - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Retail - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Hospitals - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 27: Unified Health System and funding channels in Brazil
  • Exhibit 28: Hospitals - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: Market opportunity by distribution channel
  • Exhibit 30: Product - Market share 2018-2023 (%)
  • Exhibit 31: Comparison by product
  • Exhibit 32: Basal insulin analog - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Basal insulin analog - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: NPH - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: NPH - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Market opportunity by product
  • Exhibit 37: Customer landscape
  • Exhibit 38: Application - Market share 2018-2023 (%)
  • Exhibit 39: Comparison by application
  • Exhibit 40: Type I diabetes - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 41: Type I diabetes - Year-over-year growth 2019-2023 (%)
  • Exhibit 42: Type II diabetes - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 43: Type II diabetes - Year-over-year growth 2019-2023 (%)
  • Exhibit 44: Market opportunity by application
  • Exhibit 45: Mortality by cause (2008)
  • Exhibit 46: Non-communicable disease-related mortality rate (2008)
  • Exhibit 47: Demographic indicators in Brazil (1980-2015)
  • Exhibit 48: Practical phenotypic characteristics used to differentiate between type I and type II diabetes
  • Exhibit 49: Impact of drivers and challenges
  • Exhibit 50: Vendor landscape
  • Exhibit 51: Landscape disruption
  • Exhibit 52: Vendors covered
  • Exhibit 53: Vendor classification
  • Exhibit 54: Market positioning of vendors
  • Exhibit 55: Biocon Ltd. - Vendor overview
  • Exhibit 56: Biocon Ltd. - Business segments
  • Exhibit 57: Biocon Ltd. - Organizational developments
  • Exhibit 58: Biocon Ltd. - Geographic focus
  • Exhibit 59: Biocon Ltd. - Segment focus
  • Exhibit 60: Biocon Ltd. - Key offerings
  • Exhibit 61: Biocon Ltd. - Key customers
  • Exhibit 62: Eli Lilly and Co. - Vendor overview
  • Exhibit 63: Eli Lilly and Co. - Product segments
  • Exhibit 64: Eli Lilly and Co. - Organizational developments
  • Exhibit 65: Eli Lilly and Co. - Geographic focus
  • Exhibit 66: Eli Lilly and Co. - Segment focus
  • Exhibit 67: Eli Lilly and Co. - Key offerings
  • Exhibit 68: Eli Lilly and Co. - Key customers
  • Exhibit 69: Novo Nordisk AS - Vendor overview
  • Exhibit 70: Novo Nordisk AS - Business segments
  • Exhibit 71: Novo Nordisk AS - Organizational developments
  • Exhibit 72: Novo Nordisk AS - Geographic focus
  • Exhibit 73: Novo Nordisk AS - Segment focus
  • Exhibit 74: Novo Nordisk AS - Key offerings
  • Exhibit 75: Novo Nordisk AS - Key customers
  • Exhibit 76: Sanofi - Vendor overview
  • Exhibit 77: Sanofi - Business segments
  • Exhibit 78: Sanofi - Organizational developments
  • Exhibit 79: Sanofi - Geographic focus
  • Exhibit 80: Sanofi - Segment focus
  • Exhibit 81: Sanofi - Key offerings
  • Exhibit 82: Sanofi - Key customers
  • Exhibit 83: Wockhardt Ltd. - Vendor overview
  • Exhibit 84: Wockhardt Ltd. - Business segments
  • Exhibit 85: Wockhardt Ltd. - Organizational developments
  • Exhibit 86: Wockhardt Ltd. - Geographic focus
  • Exhibit 87: Wockhardt Ltd. - Key offerings
  • Exhibit 88: Wockhardt Ltd. - Key customers
  • Exhibit 89: Validation techniques employed for market sizing
  • Exhibit 90: Definition of market positioning of vendors
目次
Product Code: IRTNTR32183

About this market

Technavio's human insulin drugs market in brazil market analysis considers sales from basal insulin analog and NPH products. Our study also finds the sales of the human insulin drugs market in brazil in retail and hospital distribution channels. In 2018, the basal insulin analog segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as flexibility of timing and dosing, less fear of dose adjustment, and fewer injections with analogs to achieve their therapeutic effect will play a significant role in the basal insulin analog segment to maintain its market position. Also, our human insulin drugs market in brazil report looks at factors such as rising prevalence of diabetes in Brazil, demographic transition in Brazil, and strategic alliance. However, high cost of human insulin drugs, unknown etiology of type I diabetes, and unavailability of specific biomarkers may hamper the growth of the human insulin drugs market in brazil over the forecast period.

Overview

Demographic transition in brazil

Brazil has undergone rapid demographic, nutritional, and epidemiological transitions, which have led to an increase in the prevalence of diabetes in this region. Currently, the youth demographic forms a significant portion of Brazil's population. Since type I diabetes affects an individual at an incredibly young age, the presence of a large younger demographic provides significant growth opportunities for vendors in the human insulin drugs market in Brazil. This demographic transition in brazil will lead to the expansion of the human insulin drugs market in brazil at a CAGR of over 5% during the forecast period.

Technological advancements

Technological advancements are expected to be one of the key factors for the growth of the human insulin drug market size in Brazil during the forecast period. The availability of novel digital equipment and data-driven devices, such as the connected care insulin delivery system, has fueled the interest of researchers in this area. The major vendors in the market are now focusing on developing novel human insulin drugs through strategic alliances, especially by partnering with research institutes and other healthcare organizations. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the human insulin drugs market in brazil during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the human insulin drugs market in brazil is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human insulin drugs market in brazil manufacturers, that include Biocon Ltd., Eli Lilly and Co., Novo Nordisk AS, Sanofi, and Wockhardt Ltd.

Also, the human insulin drugs market in brazil includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: INSULIN: AN OVERVIEW

PART 07: MARKET SEGMENTATION BY DISTRIBUTION CHANNEL

  • Market segmentation by distribution channel
  • Comparison by distribution channel
  • Retail - Market size and forecast 2018-2023
  • Hospitals - Market size and forecast 2018-2023
  • Market opportunity by distribution channel

PART 08: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Basal insulin analog - Market size and forecast 2018-2023
  • NPH - Market size and forecast 2018-2023
  • Market opportunity by product

PART 09: CUSTOMER LANDSCAPE

PART 10: MARKET SEGMENTATION BY APPLICATION

  • Market segmentation by application
  • Comparison by application
  • Type I diabetes - Market size and forecast 2018-2023
  • Type II diabetes - Market size and forecast 2018-2023
  • Market opportunity by application

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • Advent of biosimilars
  • Increasing initiatives by vendors
  • Technological advancements

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Biocon Ltd.
  • Eli Lilly and Co.
  • Novo Nordisk AS
  • Sanofi
  • Wockhardt Ltd.

PART 16: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 17: EXPLORE TECHNAVIO

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.